Abstract: A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation is disclosed. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.

Abstract: A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation is disclosed. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.

Abstract: Disclosed are a method for treating brain tumors, as well as a medicament for treating brain tumors. Provided is a medicament for treating brain tumors, the medicament containing a combination of 4-[4-cyano-2-({[(2?R,4S)-6-(isopropylcarbamoyl)-2,3-dihydrospiro[chromene-4,1?-cyclopropan]-2?-yl]carbonyl}amino)phenyl]butanoic acid or a pharmaceutically acceptable salt thereof, and an anti-PD-1 antibody. The combination exhibits an excellent effect for treating brain tumors, and is thus useful to treat brain tumors.

Abstract: A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation is disclosed. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.

Abstract: A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.

Abstract: Disclosed are a method for treating brain tumors, as well as a medicament for treating brain tumors. Provided is a medicament for treating brain tumors, the medicament containing a combination of 4-[4-cyano-2-({[(2?R,4S)-6-(isopropylcarbamoyl)-2,3-dihydrospiro[chromene-4,1?-cyclopropan]-2?-yl]carbonyl}amino)phenyl]butanoic acid or a pharmaceutically acceptable salt thereof, and an anti-PD-1 antibody. The combination exhibits an excellent effect for treating brain tumors, and is thus useful to treat brain tumors.

Abstract: A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.

Abstract: A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.

Abstract: A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.